3 studies found for:    SGN-CD33A
Show Display Options
Rank Status Study
1 Enrolling by invitation A Safety Study of SGN-CD33A in AML Patients
Conditions: Acute Myelogenous Leukemia;   Acute Myeloid Leukemia;   Acute Promyelocytic Leukemia
Interventions: Drug: HMA;   Drug: SGN-CD33A
2 Recruiting A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
Conditions: Acute Myeloid Leukemia;   Acute Myelogenous Leukemia
Interventions: Drug: Standard dose cytarabine for induction;   Drug: SGN-CD33A;   Drug: Daunorubicin;   Drug: High dose cytarabine for consolidation
3 Recruiting Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
Condition: Myelodysplastic Syndrome
Interventions: Drug: vadastuximab talirine;   Drug: Azacitidine;   Drug: Placebo (for 33A)

Indicates status has not been verified in more than two years